Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

Summary

The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.

Timeline

Start

2021-06-14

Primary completion

2023-06-06

Completion

2023-06-06

Publications

• Ekhlas D, Verbiest A, Stas M, De Meyere L, Vandermeulen G, Toth J, Geboers K, Timmermans L, Verspecht C, Wauters L, Vermeersch P, Jeppesen PB, Verbeke K, Joly F, Derrien M, Raes J, Vanuytsel T. Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome. Clin Nutr ESPEN. 2026 Jun;73:103138. doi: 10.1016/j.clnesp.2026.103138. Epub 2026 Mar 26.
• Verbiest A, Hvistendahl MK, Bolognani F, Li C, Youssef NN, Huh S, Menys A, Bhatnagar G, Vanslembrouck R, Peeters R, Sartoris R, Vermeersch P, Wauters L, Verbeke K, Jeppesen PB, Joly F, Vanuytsel T. Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study. Clin Nutr. 2024 Dec;43(12):158-166. doi: 10.1016/j.clnu.2024.10.011. Epub 2024 Oct 16.

Drugs

Indications